Explore disease and humanized preclinical models across oncology, immunology and inflammation, metabolic disease, cardiovascular and cerebrovascular research, neuroscience, renal disease, respiratory disease, and liver disease. Model availability, exact strain, induction protocol, study window, and endpoints are confirmed during technical review.
PDX studies use patient-derived tumor tissue in immunodeficient mice for oncology efficacy, PK/PD, biomarker, and tissue-analysis work.
Human tumor cell line-derived xenograft platforms span hematologic and solid-tumor indications including lung, breast, colorectal, pancreatic, gastric, liver, renal, prostate, and brain cancers.
Documented syngeneic mouse tumor platforms include colorectal, breast, melanoma, lymphoma, renal, pancreatic, lung, liver, glioma, and other murine tumor systems.
Documented orthotopic platforms include human xenograft and syngeneic tumor models across hematologic, lung, pancreatic, liver, brain, colorectal, and breast cancer settings.
Human PBMC engraftment in NOG-family mice provides a human immune-cell context for T-cell-focused immuno-oncology research and preclinical pharmacology.
The documented HSC-humanized platform engrafts human CD34+ hematopoietic stem cells into NOG-EXL mice expressing human GM-CSF and IL-3.
The documented CIA platform uses DBA/1 mice and type II collagen immunization for rheumatoid-arthritis pharmacology studies involving T- and B-cell biology.
The documented inflammatory-bowel-disease platform includes DSS-induced acute and chronic colitis mouse models for preclinical pharmacology studies.
The documented dermatology platform includes imiquimod-induced psoriasis models in both mice and rats for inflammatory skin-disease pharmacology.
Documented atopic-dermatitis platforms include OXA-, DNCB-, FITC-, and MC903-induced mouse models for inflammatory skin-disease pharmacology.
High-fat diet-induced obesity models are available in mice and rats for metabolic-disease pharmacology and integrated exposure or biomarker-oriented studies.
Documented type 2 diabetes platforms include STZ/high-fat-diet-induced rat studies and ZDF rat models for metabolic-disease pharmacology.
GLP-1R-humanized mouse models provide a human-receptor context for incretin-focused metabolic pharmacology, efficacy, exposure, and biomarker studies.
Diet-induced MASH/NASH models, including MCD-, AMLN-, and HFD/STZ-based study formats, support metabolic liver-disease pharmacology with histology, fibrosis, biomarker, and PK/PD endpoints.
Documented rat heart-failure platforms include myocardial-infarction systolic heart failure and abdominal- or aortic-arch-constriction diastolic heart-failure models.
Mouse and rat middle cerebral artery occlusion studies use a suture-occlusion approach to model cerebral ischemia for stroke-focused preclinical research.
Documented Parkinson's disease platforms include MPTP-induced mouse models, B6-hSNCA E46K/A53T mice, and 6-OHDA-induced rat models.
A mouse IgA nephropathy model is identified in the reviewed partner portfolio for immune-mediated renal disease research, with current availability confirmed case by case.
Documented pulmonary-disease platforms include bleomycin-induced rat pulmonary fibrosis and interstitial lung-injury models, with additional rodent lung-injury formats available by program.
CCl4-induced liver fibrosis is documented within the partner model portfolio alongside TAA, HSA, liver-failure, and other hepatic injury or fibrosis study formats.
We offer access to the following in vivo animal model platforms through selected labs.
Share the development context and we can align the appropriate capability, therapeutic model, species, laboratory, and data package.
Required fields are marked with an asterisk(*).
